Technology Overview
The problem we solve
Only 20–25% of first-line chemotherapy treatments are effective in lung cancer patients.
There is no available method to predict the effectiveness of chemotherapy in case of lung cancer. Among various types of first line chemotherapy, only 20-25% prove to be effective. CheMOnitor addresses a critical gap in oncology by providing an early, precise prediction of the effectiveness of chemotherapy in lung cancer. Currently, oncologists rely on imaging and biopsy-based methods that assess treatment response only after 3-5 months, leading to unnecessary toxicity, financial burden, and loss of valuable treatment time for non-responding patients.
A Precise, Early-Stage Solution
Our test provides rapid, non-invasive, and highly specific insights before full treatment cycles are completed.
This unique integration of bioanalytic and AI-supported methods offers superior accuracy, enabling oncologists to make timely, data-driven decisions, reducing unnecessary therapy and costly treatments. Additionally, our technology is designed for seamless integration into existing healthcare workflows, making it highly scalable and accessible. By filling a critical gap in precision oncology, CheMOnitor has the potential to revolutionize chemotherapy management and significantly improve patient survival rates.
How CheMOnitor Works
Our test is being developed as an In Vitro Diagnostic tool designed for routine clinical use by oncologists.
Step 1: Two non-invasive blood sample collections
Step 2: Sample preparation with minimal reagent requirement
Step 3: Fast, robust, and reliable N-glycan profile analysis
Step 4: AI-based data analysis
Step 5: Determining chemotherapy effectiveness!
CheMOnitor is going to be a IVD tool for oncologists who needs a method to predict whether a chemotherapy treatment will be effective for the certain lung cancer patient or not. The method itself is a simple blood test thus suitable for the daily clinical routine. But the underlying technology is rather unique, it combines ultra-high resolution glycomics analysis with AI based data interpretation. With our approach, we will be the first company, which can serve this essential information for the doctors.
Why Glycan Analysis?
Glycans are dynamic biomarkers that reflect how the body responds to cancer and its treatment.
Glycans play a critical role in cancer biology. Our technology focuses on the analysis of these complex molecules to provide valuable insights that are crucial to understand patient response to chemotherapy.
- Cell communication
- Tumor progression
- Immunie response
AI Integration
By combining advanced glycan profiling with AI-driven pattern recognition, CheMOnitor delivers a new level of precision in oncology—turning complex molecular data into actionable clinical insights, faster than ever before.
By integrating AI with glycoanalytical tools, we generate and analyze vast amounts of data to identify unique patterns of N-glycan profiles that traditional methods might miss. This ensures a highly accurate and personalized approach to treatment planning.
- Pattern recognition of N-glycan structures
- Personalized chemotherapy prediction
- Machine learning models trained on patient datasets